Table 2: Post-solid organ transplant t-MNs at the University of Chicago.

Patient 1Patient 2Patient 3Patient 4Patient 5

Age/sex (years)57/M56/M50/M58/F55/F
Organ transplantHeartKidneyHeartLiverKidney
Immuno-suppressive therapyCsA
MMF
Prednisone
CsA
MMF
Prednisone
CsA
azathioprine Prednisone
CsA
azathioprine Prednisone
Cytoxan
Prednisone
Latency (years)4.34.412.37.77
WHO classificationt-AML t-AMLt-MDSt-MDSt-MDS
TreatmentInduction chemo + allo-HCTInduction chemo + allo-HCTInduction chemo + auto-HCTInduction chemoSupportive care
Survival (years)11.53.61.31.9
Karyotype46XY, inv(9)c, t(10;11)Normal46XY, 55%; 46XY, del 7, 25%; 46XY, del 11, 20%Normal46XX, 55%; 46XX, inv(9)c, del 7, 41%; 46XX, inv(9)c, del 19, 4%